China’s NMPA Approves Junshi Biosciences’ Toripalimab + Bevacizumab for Advanced Hepatocellular Carcinoma
Shots:
- China’s NMPA has approved sBLA of toripalimab + bevacizumab for the 1L treatment of inoperable or metastatic HCC pts; regulatory review is ongoing globally
- Approval was based on P-III (HEPATORCH) trial assessing the safety & efficacy of toripalimab + bevacizumab vs sorafenib in 1L HCC pts (n=326) across Mainland China, China’s Taiwan & Singapore
- The trial met its 1EPs, with 31% PFS improvement (per independent review) & mOS of 20 vs 14.5mos., while also demonstrating mPFS of 5.8 vs 4mos., 24% decrease in death risk, & an ORR of 25.3% vs 6.1%; data was presented at CSCO 2024
Ref: Globenewswire | Image: Junshi Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
